The investment will add additional capacity and capabilities to a facility that makes some of Pfizer’s most closely watched experimental treatments. The Sanford plant manufactures therapies used for the company’s late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies.

source https://finance.yahoo.com/news/pfizer-invests-500-million-expanding-162744352.html?.tsrc=rss